Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Sleep Disordered BreathingAble Bodied
Interventions
DRUG

Acetazolamide + supplemental oxygen + PAP therapy

Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.

DRUG

Zolpidem + PAP therapy

The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.

DRUG

Buspirone + PAP therapy

The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.

Trial Locations (1)

48201-1916

RECRUITING

John D. Dingell VA Medical Center, Detroit, MI, Detroit

All Listed Sponsors
lead

VA Office of Research and Development

FED